Literature DB >> 12406082

Hodgkin's disease in the elderly: a population-based study.

Gail L Stark1, Katrina M Wood, Fergus Jack, Brian Angus, Stephen J Proctor, Penelope R Taylor.   

Abstract

This study evaluated the incidence and outcome of Hodgkin's disease (HD) in older patients using a population-based approach. In total, 102 patients (52 men, 50 women) aged >or= 60 years presented in the Northern Health Region of England (population of 3.09 million) between 1 January 1991 and 31 December 1998 and were studied prospectively. The age-specific incidence was 1.97/100,000 for those aged 60-69 years, and 2.18/100,000 for those aged 70 years or over. The median age of the cohort was 70 years (range 60-91) and the median follow up was 63 months (range 20-113). Out of 95 treated patients, 70 (74%) obtained complete or good partial (> 90% response) remissions. In the 60 to 69-year-old group, the disease-specific survival at 5 years was 100% for those presenting with early stage disease and 52% for those with advanced stage disease. In patients aged >70 years the 5 year disease-specific survival was 36% in patients with early stage and 14% for patients with advanced stage disease. The survival of patients with Epstein-Barr virus (EBV)-positive tumours was significantly poorer than that of patients with EBV-negative tumours (P = 0.007); median survival in the former group was 20 months versus undefined in the latter group. In total, 43 deaths were due to progressive HD and five were treatment-related. This study defined the incidence of HD in our population and demonstrated that the prognosis of elderly patients, particularly those with advanced stage disease, has not improved concurrently with that of patients aged < 60 years old. Novel approaches to assessment and treatment are necessary.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12406082     DOI: 10.1046/j.1365-2141.2002.03815.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  32 in total

Review 1.  State of the art in the treatment of Hodgkin lymphoma.

Authors:  Peter Borchmann; Dennis A Eichenauer; Andreas Engert
Journal:  Nat Rev Clin Oncol       Date:  2012-06-12       Impact factor: 66.675

2.  Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older.

Authors:  Andres Forero-Torres; Beata Holkova; Jerome Goldschmidt; Robert Chen; Gregg Olsen; Ralph V Boccia; Rodolfo E Bordoni; Jonathan W Friedberg; Jeff P Sharman; Maria Corinna Palanca-Wessels; Yinghui Wang; Christopher A Yasenchak
Journal:  Blood       Date:  2015-09-16       Impact factor: 22.113

Review 3.  Current Treatment Options for Older Patients with Hodgkin Lymphoma.

Authors:  Jordan Carter; Kevin A David; Athena Kritharis; Andrew M Evens
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

4.  Management of older Hodgkin lymphoma patients.

Authors:  Andrew M Evens; Jordan Carter; Kah Poh Loh; Kevin A David
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  The unique characteristics and management of patients over 60 years of age with classic Hodgkin lymphoma.

Authors:  Teresa V Halbsguth; Boris Böll; Peter Borchmann; Volker Diehl
Journal:  Curr Hematol Malig Rep       Date:  2011-09       Impact factor: 3.952

Review 6.  The GHSG Approach to Treating Hodgkin's Lymphoma.

Authors:  Paul J Bröckelmann; Andreas Engert
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

7.  Unusual Histology in Hodgkin's Lymphoma: Report of an Interesting Case.

Authors:  Sujata Jetley; Shaan Khetrapal; Mukta Pujani; Mohd Jaseem Hassan; Abhinav Jain
Journal:  Indian J Surg Oncol       Date:  2016-12-09

8.  Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.

Authors:  Ercole Brusamolino; Andrea Bacigalupo; Giovanni Barosi; Giampaolo Biti; Paolo G Gobbi; Alessandro Levis; Monia Marchetti; Armando Santoro; Pier Luigi Zinzani; Sante Tura
Journal:  Haematologica       Date:  2009-03-10       Impact factor: 9.941

9.  The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.

Authors:  Andrew M Evens; Fangxin Hong; Leo I Gordon; Richard I Fisher; Nancy L Bartlett; Joseph M Connors; Randy D Gascoyne; Henry Wagner; Mary Gospodarowicz; Bruce D Cheson; Patrick J Stiff; Ranjana Advani; Thomas P Miller; Richard T Hoppe; Brad S Kahl; Sandra J Horning
Journal:  Br J Haematol       Date:  2013-01-29       Impact factor: 6.998

Review 10.  Current strategies for salvage treatment for relapsed classical Hodgkin lymphoma.

Authors:  Liana Nikolaenko; Robert Chen; Alex F Herrera
Journal:  Ther Adv Hematol       Date:  2017-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.